Global /China /Healthcare /Biotechnology /688238

Shanghai Obio Technology (Group) Corp., Ltd.

688238

• SSE: 688238 • Delayed

6.79CNY -0.6%

1.00 USD

As of 14 June 2026, Shanghai Obio Technology (Group) Corp., Ltd. has a market cap of $635.33M USD, ranking #13553 globally and #4126 in China. It ranks #1217 in the Healthcare sector, and #226 in the Biotechnology industry.

Global Rank

13553

Country Rank

4126

Sector Rank

1217

Industry Rank

226

Key Stats

Market Cap

$635.33MUSD

4.31B CNY

Enterprise Value

$668.31MUSD

4.52B CNY

Revenue (TTM)

$39.17MUSD

265.39M CNY

EBITDA (TTM)

-$15.1MUSD

-102.18M CNY

Net Income (TTM)

-$33.75MUSD

-228.67M CNY

EBITDA Margin

-39%

Profit Margin

-86%

PS Ratio

16.2

PB Ratio

3.2

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Oudong Pan open_in_new

Employees

678

Founded

2013

Website

obiosh.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.6%	2.6%	0.4%	-5.1%	-8.6%	2.6%	21%	-49%	-66%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688238 和元生物技术(上海)股份有限公司 Class A ISIN: CNE1000059N9 Shares Out.: Shares Outstanding: 448.016M¹ Shares Float: 447.986M² TV: TradingView: SSE: 688238 SA: Stock Analysis: SHA: 688238 YF: Yahoo Finance: 688238.SS GF: Google Finance: SHA: 688238 BA: Barron's: 688238 MS: Morningstar: XSHG: 688238	6.79 CNY	TV: TradingView: SSE: 688238 SA: Stock Analysis: SHA: 688238 YF: Yahoo Finance: 688238.SS GF: Google Finance: SHA: 688238 BA: Barron's: 688238 MS: Morningstar: XSHG: 688238

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Shanghai Obio Technology (Group) Corp., Ltd.

Shanghai Obio Technology (Group) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing process, for basic research, translational research and clinical trials. It also provides CDMO services encompassing process development, analytical methods, IND-enabling chemistry, manufacturing, and controls; and clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products. The company was formerly known as Obio Technology (Shanghai) Corp., Ltd. and change its name to Shanghai Obio Technology (Group) Corp., Ltd. in March 2026. The company was founded in 2013 and is headquartered in Shanghai, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.44B 136.71B HKD 3K%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 2K%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.0B 54.23B CNY 1K%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.33B 49.69B CNY 1K%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 1K%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.72B 45.52B CNY 957%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 29K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 25K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 7K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 7K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 7K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 7K%	37.2	Switzerland

chevron_leftBack